NORTH CHICAGO, Ill., April 22, 2026

AbbVie has announced a landmark $1.4 billion investment to establish a state-of-the-art pharmaceutical manufacturing campus in Durham, North Carolina, marking the company’s largest-ever single-site capital investment. This strategic expansion underscores AbbVie’s commitment to strengthening its U.S. manufacturing footprint and advancing its $100 billion long-term investment plan in research, development, and production capabilities. The new 185-acre facility will integrate advanced manufacturing technologies and artificial intelligence (AI) to support the production of next-generation therapies in immunology, neuroscience, and oncology, positioning AbbVie at the forefront of biopharmaceutical innovation and global supply resilience.

Major Investment Driving Innovation and Job Creation

The Durham campus represents a significant step forward in AbbVie’s strategy to expand its manufacturing excellence and innovation capabilities in the United States. Scheduled to begin construction in 2026 and expected to be completed by the end of 2028, the facility will create 734 high-skilled jobs, including roles for engineers, scientists, and manufacturing specialists, while also generating over 2,000 construction jobs during development.

This investment highlights the importance of regional life sciences hubs, with North Carolina’s Research Triangle area offering a highly skilled workforce and strong infrastructure to support advanced pharmaceutical production. The campus will include next-generation laboratories, small volume parenteral (SVP) manufacturing facilities, warehouses, and administrative centers, designed to enable efficient production of sterile injectable medicines, which are critical for treating complex diseases.

Advanced Manufacturing and AI Integration

Advertisement

cGxPJobs Banner

A defining feature of the new facility is its integration of cutting-edge AI-driven manufacturing systems, which will enhance operational efficiency, quality control, and scalability. The campus is expected to serve as AbbVie’s U.S. center of excellence for small volume parenteral manufacturing, focusing on sterile injectable products such as vials, prefilled syringes, and cartridges used for advanced therapies.

By leveraging digital transformation and automation, AbbVie aims to streamline production processes while ensuring high-quality standards and regulatory compliance. This approach reflects a broader industry trend toward smart manufacturing in biopharma, where data-driven insights and automation are used to improve productivity and accelerate the delivery of life-saving medicines to patients worldwide.

Strengthening Global Supply and Future Outlook

The investment is part of AbbVie’s broader vision to enhance its global supply chain resilience and manufacturing capacity, ensuring reliable access to critical medicines for patients across the globe. With this project, AbbVie has committed to investing more than $2.2 billion in U.S. manufacturing over the past year, reinforcing its role as a leading innovator in the biopharmaceutical sector.

The Durham campus will not only support the company’s current portfolio but also accommodate its expanding pipeline of innovative therapies, enabling faster commercialization of new treatments. Industry experts view this move as a strategic alignment with future healthcare demands, where advanced biologics and precision medicines require highly specialized manufacturing capabilities. As AbbVie continues to expand its footprint, the new campus is expected to play a pivotal role in driving medical breakthroughs, boosting economic growth, and advancing patient care globally.

Source: AbbVie press release